Physician profile
Pushpendra K Jain
NPI 1689748634
$9,636.12
in general payments reported to CMS, 2019-2025
47 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $647 · 2021: $6,466 · 2022: $531 · 2023: $622 · 2024: $541 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,035.20 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $800.00 | 2021 | |
| Novo Nordisk INC | $587.97 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $385.30 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $296.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $244.92 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $238.89 | 2021-2024 | Korlym |
| Merz North America, INC. | $157.39 | 2020 | |
| Pfizer INC. | $147.57 | 2019-2025 | |
| Daiichi Sankyo INC. | $121.93 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $119.56 | 2020-2022 | |
| Amgen INC. | $119.47 | 2020-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $111.90 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $103.59 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $90.62 | 2020-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpendra Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.